Table 1 Comparison of clinical parameters of patients in NAFLD and non-NAFLD groups
Variables | NAFLD group (n = 41) | Non-NAFLD group (n = 40) | P |
|---|---|---|---|
Sex (male/female, n) | 23/18 | 19/21 | 0.439 |
Age (year) | 53.9 ± 10.6 | 56.9 ± 9.8 | 0.183 |
Diabetes duration (year) | 5.4 ± 4.4 | 5.8 ± 4.6 | 0.712 |
BMI (kg/m2) | 26.2 ± 4.0 | 23.9 ± 3.9 | 0.010 |
SBP (mmHg) | 139 ± 16.7 | 128 ± 15.0 | ˂0.01 |
DBP (mmHg) | 83 ± 12.4 | 75 ± 9.7 | 0.048 |
TC (mmol/L) | 5.8 ± 1.3 | 5.5 ± 1.1 | 0.315 |
TG (mmol/L) | 2.3 ± 1.9 | 1.6 ± 1.0 | 0.045 |
LDL-C (mmol/L) | 3.1 ± 0.9 | 3.2 ± 1.0 | 0.607 |
HDL-C (mmol/L) | 1.1 ± 0.3 | 1.2 ± 0.4 | 0.139 |
ApoA (mmol/L) | 1.4 ± 0.3 | 1.4 ± 0.3 | 0.867 |
ApoB (mmol/L) | 1.2 ± 0.3 | 1.2 ± 0.7 | 0.864 |
Lipoprotein (a) (mg/dL) | 288.2 ± 161.4 | 282.5 ± 178.5 | 0.528 |
ALT (U/L) | 49.9 ± 60.9 | 21.7 ± 14.7 | ˂0.01 |
AST (U/L) | 31.5 ± 26.1 | 19.2 ± 7.4 | ˂0.01 |
GGT (U/L) | 39.9 ± 30.2 | 28.9 ± 24.8 | ˂0.01 |
ALP (U/L) | 91.7 ± 31.6 | 83.54 ± 25.7 | 0.192 |
UA (mmol/L) | 358.9 ± 90.9 | 314.2 ± 88.5 | 0.030 |
TNF-α (pg/ml) | 29.4 ± 1.72 | 21.7 ± 3.03 | 0.036 |
IL-6 (pg/ml) | 41.1 ± 0.47 | 28.4 ± 5.27 | ˂0.01 |
IL-10 (pg/ml) | 51.6 ± 1.52 | 66.7 ± 3.38 | ˂0.01 |
SCr (umol/L) | 64.4 ± 21.8 | 64.0 ± 24.1 | 0.742 |
BUN (mmol/L) | 5.0 ± 1.7 | 5.1 ± 1.3 | 0.787 |
CYC (mg/L) | 1.2 ± 0.4 | 1.1 ± 0.3 | 0.741 |
FPG (mmol/L) | 9.2 ± 2.6 | 9.2 ± 2.3 | 0.913 |
2 h PG (mmol/L) | 18.1 ± 4.7 | 17.0 ± 4.2 | 0.269 |
HbA1c (%) | 9.6 ± 2.2 | 8.6 ± 2.1 | 0.047 |
FCP (mmol/L) | 1.7 ± 0.8 | 1.1 ± 0.7 | ˂0.01 |
2 h CP (mmol/L) | 4.7 ± 2.4 | 3.1 ± 2.0 | ˂0.01 |
HOMA-IR | 3.4 ± 1.9 | 2.1 ± 1.0 | ˂0.01 |
HOMA-IS | 31.6 ± 20.5 | 21.2 ± 14.9 | 0.014 |
ASCVD (n, %) | 34 (82.9) | 32 (80.0) | 0.735 |
DN (n, %) | 12 (29.2) | 9 (22.5) | 0.487 |
DPN (n, %) | 19 (46.3) | 16 (40.0) | 0.565 |
DR (n, %) | 29 (70.7) | 23 (57.5) | 0.214 |